Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bacheler L, Albrecht MA. “Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz,” AIDS, 2003; 17:2395-2396.

Gilbert PB, Bosch RJ, Hudgens MG. “Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials,” Biometrics. 2003; 59:531-541.

Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. “Genetic correlates of efavirenz hypersusceptibility,” AIDS, 2004; 18:1781-1785.

Bosch RJ, Pierce C, Spritzler J, Kendall MA, Jacobson JM, Schock B, Siminski S. “A reporting tool for real-time assessment of study data availability,” Clin Trials. 2004; 1:339-340.

Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. “Depletion of latent HIV-1 infection in vivo: a proof-of-concept study,” Lancet, 2005; 366:549-555.

Sharghi N, Bosch RJ, Mayer K, Essex M, Seage GR. “The development and utility of a clinical algorithm to predict early HIV-1 infection,” JAIDS, 2005; 40:472-478.

Venkatesh PA, Bosch RJ, McIntosh K, Mugusi F, Msamanga G, Fawzi WW. “Predictors of incident tuberculosis among HIV-1-infected women in Tanzania,” Int J Tuberc Lung Dis, 2005; 9:1105-1111.

Clark SA, Shulman NS, Bosch RJ, Mellors JW. “Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors,” AIDS, 2006; 20:981-984.

Weinberg A, Tierney C, Kendall MA, Bosch RJ, Patterson-Bartlett J, Erice A, et al. “Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy,” J Infect Dis, 2006; 193:488-493.

Muthayya S, Kurpad AV, Duggan CP, Bosch RJ, Dwarkanath P, Mhaskar A, Mhaskar R, Thomas A, Vaz M, Bhat S, Fawzi WW. “Low maternal vitamin B12 status is associated with intrauterine growth retardation in urban South Indians,” Eur J Clin Nutr, 2006; 60:791-801.

Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, Boswell SL, Mathews WC, Bangsberg DR, Martin J, Whalen CC, Sieg S, Yadavalli S, Deeks SG, Lederman MM. “Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection,” JAMA, 2006; 296:1498-1506.

Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R. “A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024),” J Infect Dis. 2006; 194:1672-1676.

Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. “Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment,” JAIDS, 2006; 43:433-435.

Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA; for the ACTG A5001 Team. “Pretreatment Factors Associated With 3-Year (144-Week) Virologic and Immunologic Responses to Potent Antiretroviral Therapy,” JAIDS, 2006 Nov 30; [Epub ahead of print]